---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-029913"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T22:10:29.069508+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics appoints Jill A. Howe as CFO effective Nov 14, 2022

## Summary
- Ms. Howe will receive an annual salary of $415,000 and a $50,000 sign-on bonus.
- She is eligible for an annual bonus targeted at 40% of salary and granted a stock option for 1,000,000 shares.
- Her prior roles include CFO of DTx Pharma, VP Finance at Gossamer Bio (GOSS), and controller at Amplyx.
- CEO Brian Culley and Sr. Director Alexandra Hernandez will step down from interim CFO and principal accounting officer roles.
- Ms. Howe also serves on boards of Biora Therapeutics (BIOR) and Codagenix Inc.

## SEC filing metadata
- accession: 0001493152-22-029913
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/0001493152-22-029913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-029913
- JSON: https://secwatch.observer/filing/0001493152-22-029913.json
- Plain text: https://secwatch.observer/filing/0001493152-22-029913.txt

## Key facts
- Executive change
  Jill A. Howe was appointed as Chief Financial Officer at Lineage Cell Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On October 28, 2022, Lineage Cell Therapeutics, Inc. (“Lineage,” “we,” “us,” “our,” or the “Company”) appointed Jill A. Howe as its Chief Financial Officer, effective November 14, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/0001493152-22-029913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.